Alzheimer’s disease (AD) is a complex, neurodegenerative pathology showing, among others,
high cholinergic and neurotransmitter deficits, oxidative stress, inflammation, Aβ-aggregation resulting in
senile plaques formation, and hyperphosphorylation of tau-protein leading to neurofibrillary tangles. Due
to its multifactorial and complex nature, multitarget directed small-molecules able to simultaneously inhibit
or bind diverse biological targets involved in the progress and development of AD are considered
now the best therapeutic strategy to design new compounds for AD therapy. Among them, tacrine is a very
well known standard-gold ligand, and natural products have been a traditional source of new agents for
diverse therapeutic treatments. In this review, we will update recent developments of multitarget tacrinenatural
products hybrids for AD therapy.
Keywords: Acetylcholinesterase, Alzheimer's disease, antioxidants, butyrylcholinesterase, multitarget-directed
ligands, natural products, tacrine.
Rights & PermissionsPrintExport